ATORX.ST - Alligator Bioscience AB (publ)
| Previous Close | 6.20 |
| Open | 6.09 |
| Bid | 6.00 x 0 |
| Ask | 6.14 x 0 |
| Day's Range | 5.80 - 6.30 |
| 52 Week Range | 4.62 - 26.85 |
| Volume | 74,594 |
| Avg. Volume | 203,497 |
| Market Cap | 435.47M |
| Beta (5Y Monthly) | 0.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.94 |
| Earnings Date | Apr 23, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.00 |
- PR Newswire
Alligator Bioscience Informs About Temporary Halt of Recruitment of New Patients due to the COVID-19 Pandemic
Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today a temporary halt in the recruitment of new patients to the company's ongoing Phase I clinical trials with the drug candidates ATOR-1015 and ATOR-1017. Patients currently enrolled in clinical studies are expected to continue with their scheduled visits as planned. The company intends to, in consultation with clinical sites and authorities, resume the recruitment of patients as soon as possible.
- PR Newswire
Notice of Annual General Meeting in Alligator Bioscience AB (publ)
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
- PR Newswire
Alligator Bioscience Appoints Andreas Johannesson as interim Chief Financial Officer
Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that Andreas Johannesson has been appointed interim CFO, effective 5 March 2020. The recruitment process for a permanent CFO is ongoing. As previously announced, Per-Olof Schrewelius will leave the position as CFO at Alligator.
- PR Newswire
Alligator Bioscience's Annual Report 2019 Published
Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that the Swedish version of the Annual Report 2019 is available on the company website www.alligatorbioscience.com. An English version will follow shortly.
- Simply Wall St.
Per-Olof Schrewelius Is The Chief Financial Officer of Alligator Bioscience AB (publ) (STO:ATORX) And They Just Spent kr86k On Shares
Whilst it may not be a huge deal, we thought it was good to see that the Alligator Bioscience AB (publ) (STO:ATORX...
- PR Newswire
Alligator Bioscience AB Year-end Report January-December 2019
"2019 was the year when Alligator entered the clinical phase on a broad front. At the beginning of the year, we had one clinical project and at year-end, the number had increased to four", commented CEO Per Norlén.
- Simply Wall St.
Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- PR Newswire
Alligator Bioscience: First Patient Dosed With ATOR-1017 Developed for Metastasized Cancer
Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the first patient has been successfully dosed in the Phase I study with the wholly owned 4-1BB antibody ATOR-1017, which is being developed for the treatment of metastasized cancer.
- Simply Wall St.
How Much Are Alligator Bioscience AB (publ) (STO:ATORX) Insiders Spending On Buying Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
- PR Newswire
Alligator Bioscience AB Appoints Chief Operating Officer
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Dr Malin Carlsson as Chief Operating Officer. She most recently comes from a position as Vice President, Head of Translational Medicine at Ferring Pharmaceuticals in Copenhagen.
- PR Newswire
Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting
- Preclinical Data Show that ALG.APV-527 is Well Tolerated with Repeated Dosing - Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti-tumor Activity and Induces an Immunological Memory Response ...
- PR Newswire
Alligator Bioscience: ATOR-1017 Induces Long-Lasting Immunity - New Preclinical Data to be Presented at SITC 34th Annual Meeting
LUND, Sweden, Nov. 6, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the company will present new preclinical data showing that their drug candidate ATOR-1017 can induce a long-lasting immunological memory which is of great importance in a potential future patient setting. The results will be presented at the ongoing Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting. The ATOR-1017 drug candidate is in development for the treatment of metastasized cancer.
- PR Newswire
Alligator Bioscience AB Interim Report January-September 2019
STOCKHOLM , Oct. 24, 2019 /PRNewswire/ -- " We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 substance to, with ...
- Simply Wall St.
If You Had Bought Alligator Bioscience (STO:ATORX) Stock A Year Ago, You'd Be Sitting On A 56% Loss, Today
The nature of investing is that you win some, and you lose some. And there's no doubt that Alligator Bioscience AB...
- Simply Wall St.
Alligator Bioscience AB (publ) (STO:ATORX): What Does Its Beta Value Mean For Your Portfolio?
If you own shares in Alligator Bioscience AB (publ) (STO:ATORX) then it's worth thinking about how it contributes to...
